Esperion Ebitda vs Gross Profit Analysis

ESPR Stock

USD 2.57 0.05 1.98%

Esperion Therapeutics financial indicator trend analysis is much more than just examining Esperion Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Esperion Therapeutics is a good investment. Please check the relationship between Esperion Therapeutics Ebitda and its Gross Profit accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Esperion Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Esperion Stock, please use our How to Invest in Esperion Therapeutics guide.

Ebitda vs Gross Profit

Ebitda vs Gross Profit Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Esperion Therapeutics Ebitda account and Gross Profit. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Esperion Therapeutics' Ebitda and Gross Profit is 0.58. Overlapping area represents the amount of variation of Ebitda that can explain the historical movement of Gross Profit in the same time period over historical financial statements of Esperion Therapeutics, assuming nothing else is changed. The correlation between historical values of Esperion Therapeutics' Ebitda and Gross Profit is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebitda of Esperion Therapeutics are associated (or correlated) with its Gross Profit. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Gross Profit has no effect on the direction of Ebitda i.e., Esperion Therapeutics' Ebitda and Gross Profit go up and down completely randomly.

Correlation Coefficient

0.58

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Ebitda

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Esperion Therapeutics minus its cost of goods sold. It is profit before Esperion Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Most indicators from Esperion Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Esperion Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Esperion Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Esperion Stock, please use our How to Invest in Esperion Therapeutics guide.As of 11/26/2024, Selling General Administrative is likely to drop to about 64.1 M. In addition to that, Issuance Of Capital Stock is likely to drop to about 25.1 M

	2023	2024 (projected)
Interest Income	4.0M	3.5M
Reconciled Depreciation	250K	432.3K

Interest Income Reconciled Depreciation

Esperion Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock	Non Currrent Assets Other	Intangible Assets	Short Term Investments	Other Liab
Total Assets		0.3	0.48	0.4	-0.43	0.45	-0.01	-0.52	0.48	0.74	0.54	0.74	0.49	0.34	0.5	0.72	0.26	0.49	0.27	0.98	0.03	0.39	-0.22	-0.4	0.43	-0.66
Short Long Term Debt Total	0.3		0.91	0.92	-0.5	0.68	0.91	-0.89	0.48	0.33	-0.24	0.33	0.91	0.93	0.91	0.35	0.18	0.93	0.73	0.37	0.91	0.95	0.44	-0.17	-0.38	-0.71
Other Current Liab	0.48	0.91		0.98	-0.68	0.76	0.72	-0.97	0.73	0.53	-0.27	0.53	0.91	0.91	0.91	0.64	0.26	0.95	0.76	0.58	0.76	0.92	0.34	-0.25	-0.27	-0.78
Total Current Liabilities	0.4	0.92	0.98		-0.64	0.75	0.76	-0.96	0.76	0.46	-0.32	0.46	0.89	0.92	0.88	0.57	0.26	0.92	0.78	0.51	0.79	0.91	0.32	-0.25	-0.28	-0.72
Total Stockholder Equity	-0.43	-0.5	-0.68	-0.64		-0.49	-0.22	0.75	-0.65	-0.68	0.38	-0.68	-0.59	-0.43	-0.77	-0.89	-0.21	-0.76	-0.29	-0.58	-0.41	-0.48	-0.48	0.16	0.32	0.53
Property Plant And Equipment Net	0.45	0.68	0.76	0.75	-0.49		0.39	-0.66	0.71	0.73	-0.26	0.73	0.52	0.57	0.71	0.56	0.25	0.73	0.94	0.55	0.47	0.55	0.42	0.0	-0.41	-0.45
Net Debt	-0.01	0.91	0.72	0.76	-0.22	0.39		-0.71	0.24	-0.1	-0.26	-0.1	0.8	0.87	0.69	-0.01	0.15	0.72	0.55	0.02	0.92	0.88	0.31	-0.06	-0.31	-0.54
Retained Earnings	-0.52	-0.89	-0.97	-0.96	0.75	-0.66	-0.71		-0.7	-0.52	0.21	-0.51	-0.95	-0.9	-0.94	-0.68	-0.27	-0.96	-0.63	-0.62	-0.76	-0.92	-0.31	0.28	0.2	0.83
Accounts Payable	0.48	0.48	0.73	0.76	-0.65	0.71	0.24	-0.7		0.61	-0.29	0.6	0.51	0.54	0.55	0.73	0.25	0.61	0.65	0.6	0.29	0.49	0.09	-0.26	-0.09	-0.5
Cash	0.74	0.33	0.53	0.46	-0.68	0.73	-0.1	-0.52	0.61		0.03	1.0	0.36	0.23	0.6	0.85	0.11	0.59	0.5	0.82	0.09	0.27	0.34	-0.27	-0.2	-0.47
Non Current Assets Total	0.54	-0.24	-0.27	-0.32	0.38	-0.26	-0.26	0.21	-0.29	0.03		0.03	-0.06	-0.18	-0.2	-0.09	0.04	-0.23	-0.31	0.35	-0.37	-0.12	-0.51	-0.19	0.69	-0.16
Cash And Short Term Investments	0.74	0.33	0.53	0.46	-0.68	0.73	-0.1	-0.51	0.6	1.0	0.03		0.36	0.23	0.6	0.85	0.1	0.59	0.5	0.81	0.08	0.27	0.34	-0.27	-0.2	-0.47
Common Stock Total Equity	0.49	0.91	0.91	0.89	-0.59	0.52	0.8	-0.95	0.51	0.36	-0.06	0.36		0.95	0.9	0.49	0.19	0.91	0.53	0.54	0.78	0.98	0.23	-0.29	-0.11	-0.89
Common Stock Shares Outstanding	0.34	0.93	0.91	0.92	-0.43	0.57	0.87	-0.9	0.54	0.23	-0.18	0.23	0.95		0.8	0.33	0.22	0.84	0.67	0.4	0.83	0.98	0.16	-0.25	-0.16	-0.79
Non Current Liabilities Total	0.5	0.91	0.91	0.88	-0.77	0.71	0.69	-0.94	0.55	0.6	-0.2	0.6	0.9	0.8		0.66	0.22	1.0	0.62	0.59	0.79	0.86	0.51	-0.2	-0.36	-0.76
Other Current Assets	0.72	0.35	0.64	0.57	-0.89	0.56	-0.01	-0.68	0.73	0.85	-0.09	0.85	0.49	0.33	0.66		0.27	0.65	0.32	0.82	0.17	0.37	0.23	-0.28	-0.05	-0.55
Other Stockholder Equity	0.26	0.18	0.26	0.26	-0.21	0.25	0.15	-0.27	0.25	0.11	0.04	0.1	0.19	0.22	0.22	0.27		0.23	0.21	0.27	0.22	0.18	-0.1	0.06	0.2	-0.03
Total Liab	0.49	0.93	0.95	0.92	-0.76	0.73	0.72	-0.96	0.61	0.59	-0.23	0.59	0.91	0.84	1.0	0.65	0.23		0.67	0.59	0.8	0.89	0.48	-0.22	-0.35	-0.77
Property Plant And Equipment Gross	0.27	0.73	0.76	0.78	-0.29	0.94	0.55	-0.63	0.65	0.5	-0.31	0.5	0.53	0.67	0.62	0.32	0.21	0.67		0.36	0.56	0.62	0.34	-0.01	-0.41	-0.41
Total Current Assets	0.98	0.37	0.58	0.51	-0.58	0.55	0.02	-0.62	0.6	0.82	0.35	0.81	0.54	0.4	0.59	0.82	0.27	0.59	0.36		0.1	0.43	-0.12	-0.4	0.32	-0.69
Short Term Debt	0.03	0.91	0.76	0.79	-0.41	0.47	0.92	-0.76	0.29	0.09	-0.37	0.08	0.78	0.83	0.79	0.17	0.22	0.8	0.56	0.1		0.83	0.44	-0.21	-0.44	-0.47
Common Stock	0.39	0.95	0.92	0.91	-0.48	0.55	0.88	-0.92	0.49	0.27	-0.12	0.27	0.98	0.98	0.86	0.37	0.18	0.89	0.62	0.43	0.83		0.25	-0.25	-0.18	-0.84
Non Currrent Assets Other	-0.22	0.44	0.34	0.32	-0.48	0.42	0.31	-0.31	0.09	0.34	-0.51	0.34	0.23	0.16	0.51	0.23	-0.1	0.48	0.34	-0.12	0.44	0.25		0.19	-0.91	-0.09
Intangible Assets	-0.4	-0.17	-0.25	-0.25	0.16	0.0	-0.06	0.28	-0.26	-0.27	-0.19	-0.27	-0.29	-0.25	-0.2	-0.28	0.06	-0.22	-0.01	-0.4	-0.21	-0.25	0.19		-0.2	0.32
Short Term Investments	0.43	-0.38	-0.27	-0.28	0.32	-0.41	-0.31	0.2	-0.09	-0.2	0.69	-0.2	-0.11	-0.16	-0.36	-0.05	0.2	-0.35	-0.41	0.32	-0.44	-0.18	-0.91	-0.2		-0.07
Other Liab	-0.66	-0.71	-0.78	-0.72	0.53	-0.45	-0.54	0.83	-0.5	-0.47	-0.16	-0.47	-0.89	-0.79	-0.76	-0.55	-0.03	-0.77	-0.41	-0.69	-0.47	-0.84	-0.09	0.32	-0.07

Click cells to compare fundamentals

Esperion Therapeutics Account Relationship Matchups

Esperion Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	214.4M	353.3M	381.6M	247.9M	205.8M	181.9M
Other Current Liab	34.6M	37.8M	37.4M	40.6M	62.7M	65.9M
Total Current Liabilities	66.1M	94.1M	73.4M	92.3M	156.2M	164.0M
Total Stockholder Equity	(695.3M)	(838.8M)	(1.1B)	(1.3B)	(455.0M)	(432.2M)
Property Plant And Equipment Net	2.7M	7.3M	2.6M	1.2M	4.7M	4.9M
Net Debt	(164.6M)	(119.6M)	51.3M	136.2M	458.7M	481.6M
Retained Earnings	(695.3M)	(838.8M)	(1.1B)	(1.3B)	(1.5B)	(1.5B)
Accounts Payable	28.9M	52.0M	17.6M	23.0M	31.7M	33.3M
Cash	166.1M	305.0M	208.9M	124.8M	82.2M	91.3M
Non Current Assets Total	2.7M	7.4M	52.6M	1.3M	4.7M	4.5M
Cash And Short Term Investments	166.1M	305.0M	208.9M	124.8M	82.2M	91.8M
Common Stock Shares Outstanding	27.1M	27.5M	28.9M	66.4M	103.1M	108.3M
Liabilities And Stockholders Equity	(500.8M)	(389.4M)	(527.8M)	(768.3M)	205.8M	216.1M
Non Current Liabilities Total	128.4M	355.3M	505.2M	479.4M	504.6M	529.8M
Other Current Assets	10.9M	12.4M	12.3M	10.9M	4.7M	4.6M
Other Stockholder Equity	(50K)	742.7M	909.4M	1.0B	1.1B	1.1B
Total Liab	194.5M	449.4M	578.5M	571.7M	660.8M	693.8M
Property Plant And Equipment Gross	2.7M	7.3M	664K	164K	6.7M	7.0M
Total Current Assets	211.7M	345.9M	329.0M	246.7M	201.1M	160.4M
Accumulated Other Comprehensive Income	(845K)	(319K)	23K	0.0	(31K)	(2K)
Non Currrent Assets Other	(34.7M)	(7.4M)	50M	(42.1M)	(1.0)	(1.05)
Short Term Investments	165.7M	99.1M	34.7M	0.0	50.4M	42.1M
Property Plant Equipment	1.1M	1.3M	664K	164K	188.6K	179.2K
Net Tangible Assets	19.9M	(96.2M)	(196.9M)	(323.8M)	(291.4M)	(276.8M)
Retained Earnings Total Equity	(695.3M)	(838.8M)	(1.1B)	(1.3B)	(1.2B)	(1.1B)
Capital Surpluse	715.2M	797.7M	964.4M	1.1B	1.2B	676.3M
Long Term Investments	34.7M	0.0	50.4M	42.1M	37.9M	29.2M
Net Invested Capital	20.0M	83.2M	61.3M	(63.9M)	(193.4M)	(183.7M)

Pair Trading with Esperion Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Esperion Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Esperion Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Esperion Stock

0.86	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.83	AGL	agilon health	Pair Corr
0.82	ME	23Andme Holding	Pair Corr
0.82	NKTX	Nkarta Inc	Pair Corr
0.81	MTEM	Molecular Templates	Pair Corr

The ability to find closely correlated positions to Esperion Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Esperion Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Esperion Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Esperion Therapeutics to buy it.

The correlation of Esperion Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Esperion Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Esperion Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Esperion Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Esperion Stock Analysis

When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC